CAPRELSA 300MG

Description

Caprelsa 300mg is a type of targeted therapy called a tyrosine kinase inhibitor. A kinase is an enzyme which help to cell growth and it acts by targeting receptors present on the cancer cells.

Caprelsa 300mg targets epidermal growth factor (EGFR) and vascular endothelial growth factor receptors (VEGF).

Caprelsa 300mg is a prescription drug which is used under the guidance of medical practioners

Usage of Caprelsa

The Caprelsa 300mg is used for the therapy of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Mechanism of action

Vandetanib is a group of cancer-fighting medications known as anticancer and more especially to a class of medications called receptor tyrosine kinase inhibitors. These medications are antitumor medications which reduces the growth of blood vessels which fodder nutrients to cancer cells. By reducing the growth of these blood vessels, Vandetanib can help decrease the tumors sizes, which are collections of cancer cells. Vandetanib also works directly on cancer cells to destroy them or slow down the speed at which they grow.

ADME Properties

Time to high plasma level is 6 hr (range 4-10 hr) and steady state is 3 months

Bounding of plasma protein is 90% and volume of distribution is 7450L

Caprelsa 300mg is metabolized by CYP3A4

The drug elimination through feces 44% and via urine collection period of 21 day after single dose.

Dosage and administration

The Caprelsa prescribed dose is 300mg administrated orally once daily until disease progression or unacceptable toxicity occurs

Do not crush the tablets, disperse the tablet in 2 ounces of water by stirring 10 minutes approximately.

Be careful, do not use other liquids for dispersion and swallow the medicine soon after dispersion, if any remaining residue with 4 additional ounces of water and swallow.

Th dispersion liquid can be administrated via nasogastric or gastrostomy tubes.

Side effects

Caprelsa 300mg has some side effects as follows

• Headache
• Fatigue
• Kidney problems
• Dry skin
• Vomiting
• Weakness
• Irregular heart beat
• Difficulty sleeping
• Low blood sugar
• Abdominal pain
• Poor appetite
• Weight loss
• Diarrhea
• Rash
• Elevated Liver Enzymes (ALT)
• Low calcium levels
• Acne
• High blood pressure
• Nausea
• Low white blood cell count
• Photosensitivity (sensitivity to sunlight)
• Bleeding
• Anemia
• Liver tests increased (bilirubin)
• Itching
• Heartburn
• Cough
• Upper respiratory infection
• Depression

Drug interaction

While interaction with a strong CYP3A4 inducer will decreased Vandetanib plasma concentration. Hence avoid concomitant use of known strong CYP3A4 inducers during Caprelsa 300mg treatment.

When patients getting Caprelsa 300mg with drugs that are transported by OCT2 will increased plasma concentration of metformin.

When patients getting Caprelsa 300mg with digoxin will increased plasma concentration of digoxin.

Avoid Interaction of Caprelsa 300mg with agents which may prolong the QT interval.

Contraindication

Congenital long QT syndrome.

Precautions

• While administrating Caprelsa which will have Effective CYP3A4 inducers decreased exposure to Vandetanib by up to 40%; however, no clinically significant effect on exposure to Vandetanib was observed in the presence of the potent CYP3A4 inhibitors.
• While administrating Caprelsa producing Fatal skin reactions, involving with Stevens-Johnson syndrome and serious toxic epidermal necrolysis resulted; systemic treatment such as corticosteroids may be required; permanently blocks therapy for severe skin reactions.
• While administrating Caprelsa will produce Interstitial lung disease (ILD), causes in death has been reported; interfere with Vandetanib and examine unexplained Dyspnea, cough, and fever; applicable measures should be taken for ILD
• Ischemic cerebrovascular events, haemorrhage, heart failure, diarrhea, hypothyroidism, hypertension, and reversible posterior leukoencephalopathy syndrome, have been observed
• Can cause risk of fetal when administered to pregnant women; Do not get pregnancy while getting Vandetanib and for 4 months following treatment

Pregnancy

Caprelsa 300mg is embryotoxic and fetotoxic, due to pharmacological action treatment will causes harm to fetal when administered to a pregnant woman

Lactation

Advise females not to breastfeed during treatment and for 4 months after final dose.

Storage

Caprelsa 300mg tablets should be stored at 25⁰C.     

Missed dose

If dose is failed to take, then have the dose immediate before reach of next dose time or swap the missed dose and follow the normal schedule. Do not have extra dose which leads to over dosage. Avoid taking missed dose within 12 hours of the next dose.

Must Consult the doctor about missed dose and overdose